Researchers have successfully modified CD4+ T cells with chimeric antigen receptors (CARs) to specifically recognize and target amyloid-β plaques characteristic of Alzheimer's pathology. These engineered immune cells demonstrated the ability to migrate to sites of neurodegeneration and engage with pathological protein deposits directly within brain tissue. This immunotherapeutic approach represents a significant departure from conventional Alzheimer's treatments, which have largely focused on systemic drug delivery or passive immunization strategies. CAR-T therapy has revolutionized cancer treatment by reprogramming patients' own T cells to attack malignant cells with unprecedented precision. Adapting this platform for neurodegenerative disease could offer several advantages: targeted clearance of toxic protein aggregates, potential for long-lasting therapeutic effects through memory T cell formation, and reduced systemic side effects compared to broad immunosuppression. However, critical questions remain about blood-brain barrier penetration, neuroinflammatory responses, and long-term safety of introducing activated immune cells into the central nervous system. The approach will require extensive safety validation given the brain's immune-privileged status and the irreversible nature of CAR-T modifications.